Cell cycle progression is controlled by cyclin-dependent kinases (CDKs) that are activated by cyclin binding (Sherr, 1994; Morgan, 1995) and inhibited by CDK inhibitors (CDKIs) (Reed et al, 1994; Sherr and Roberts, 1999) . Two classes of CDKIs negatively regulate the cell cycle (Sherr and Roberts, 1995; Harper and Elledge, 1996; Xiong, 1996) . One class, the inhibitor of CDK4 (INK4) family, which consists of p15 INK4B , p16 INK4A , p18 1NK4C and p19 INK4D , specifically binds CDK4 or CDK6 and inhibits cyclin D association (Serrano et al, 1993; Guan et al, 1994; Hannon and Beach, 1994; Hirai et al, 1995) . The other class of CDKIs, the kinase inhibitor protein (KIP) family, p21 WAF1/CIP1 , p27 KIP1 and p57 KIP2 , binds and inhibits cyclin-bound CDKs (Harper et al, 1993; Toyoshima and Hunter, 1994; Lee et al, 1995) .
Recent investigations show that exogenous induction of CDKIs induces growth arrest or apoptosis in tumour cells, indicating the potential use of CDKIs as a therapeutic tool (Guan et al, 1994; Craig et al, 1997; Hiromura et al, 1999) . However, it has not been fully investigated which CDKI is the most useful for cancer therapy and whether normal tissues are affected by CDKI expression. To address these issues, in the present study, we compared the antitumour effect of CDKIs on malignant glioma cell lines and cultured astrocytes by using recombinant adenoviral vectors that express CDKIs (p16  INK4A , p18  INK4C , p19  INK4D , p21   WAF1/CIP1 and p27 KIP1 ).
MATERIALS AND METHODS

Cells
Malignant glioma cells (A172, GB-1, T98G, U87-MG, U251-MG and U373-MG) (Komata et al, 2000) and cultured astrocytes RNB (Kondo et al, 1996) were cultured in Dulbecco's modified Eagle's medium (DMEM, GIBCO BRL, Grand Island, NY, USA) supplemented with 10% fetal bovine serum (GIBCO BRL), 4 mM glutamine, 100 U ml À1 penicillin and 100 mg ml À1 streptomycin.
Construction of recombinant adenoviral vectors
The recombinant AdMH4p16, AdMHp18, AdMH4p19 , AdMH4p21  and AdMH4p27 containing p16  INK4A , p18  INK4C , p19  INK4D ,  p21 WAF1/CIP1 and p27 KIP1 were kindly supplied from Dr FL Graham (McMaster University, Ontario, Canada). As described previously (Schreiber et al, 1999) , human p16 cDNA (pBluescriptSK-p16) was obtained from Dr D Beach (Cold Spring Harbor, New York, USA). pxep21, pAdcp17 and pAdcp19 were obtained from Dr T Thompson (Baylor College of Medicine, Houston, TX, USA), and pSCZhuwtp27 was a gift from Dr J Roberts (Fred Hutchison Cancer Research Center, Seattle, WA, USA). AdBHGD1,3 containing El and E3 deletions is a control recombinant adenovirus that has identical backbone sequences to the adenoviral constructs expressing CDKIs. et al, 2000) . To achieve the infectivity of 490%, A172, GB-1, U87-MG, U251-MG, U373-MG and RNB cells were tested at a multiplicity of infection (MOI) of 60 PFU cell À1 . On the other hand, T98G cells were infected with 180 MOI. The percentage of cell viability was calculated from the mean cell viability of treated cells divided by that of cells with control treatment. To detect the expression of CDKI in infected cells, the immunoblotting assays using anti-CDKI antibody (Santa Cruz Biotechnology, Santa Cruz, CA, USA) were performed as described previously (Kondo et al, 1996) .
Detection of apoptotic or autophagic cell death
To detect apoptosis, the terminal deoxynucleotidyl transferase (Tdt)-mediated nick end labelling (TUNEL) analysis was performed as described previously (Komata et al, 2000) . To detect autophagic changes in infected cells, cells were stained with acridine orange (Poly-sciences, Warrington, PA, USA) as described previously (Paglin et al, 2001) . At 2 days after adenoviral infection, acridine orange was added at a final concentration of 1 mg ml À1 for 15 min. Microphotographs were obtained with a fluorescence microscope.
Statistical analysis
The data were expressed as means 7s.d. Statistical analysis was performed by using Student's t-test (two-tailed). The criterion for statistical significance was taken as Po0.05.
RESULTS
Effect of CDKI overexpression on viability of malignant glioma cells
To investigate the effect of CDKI on malignant glioma cell lines, cell viability was determined 3 or 5 days after adenoviral infection. As shown in Figure 1, . As shown in Figure 2 , the effect of p27 KIP1 overexpression was not significant for RNB cells, while the viability of U373-MG cells decreased to 15% of the control (Po0.005). This result suggested that p27 KIP1 -based therapy will be selective for tumour cells.
Effect of p27
KIP1 on induction of apoptosis or autophagy in U373-MG cells
To determine the type of cell death induced by AdMH4p27 KIP1 , we first performed the TUNEL staining. The incidence of TUNELpositive cells in U373-MG cells treated with AdBHGD1,3 or AdMH4p27 KIP1 for 3 or 5 days was less than 1%. Next, we investigated the changes in the cellular acidic compartments to detect the occurrence of autophagic cell death. Vital staining of U373-MG cells with acridine orange revealed the appearance of acidic vesicular organelles (AVO) 3 days after AdMH4p27 KIP1 infection (Figure 3 ). The staining of p27 KIP1 -infected cells clearly showed punctuate acidic vesicles that were diffusely distributed in cytoplasm. In contrast, there was no change of fluorescent signals in RNB cells treated with AdBHGD1,3 or AdMH4p27
KIP1
. These results indicated that the antitumour effect of p27 KIP1 on malignant glioma cells was because of autophagic cell death.
DISCUSSION
In the present study, we have demonstrated that p27
KIPl shows a greater antitumour effect than the other CDKIs (p16 INK4A , ) against six human malignant glioma cell lines. p27 KIPl -infected tumour cells undergo autophagy, but not apoptotic cell death, while overexpression of p27 KIP1 does not inhibit viability of cultured astrocytes. Our findings provide new insights into the potential use of p27 KIP1 as a novel therapeutic tool. p27 KIP1 plays a central role in the negative control of cell growth. p27
KIPl is generally expressed at high levels in cells arrested by treatment with transforming growth factor-b, contact inhibition or serum deprivation (Koff et al, 1993; Polyak et al, 1994) . In contrast, p27 KIP1 declines in the presence of mitogenic growth factor signalling or interleukin-2 (Nourse et al, 1994; Cheng et al, 1998) . p27 KIP1 -deficient mice develop a variety of abnormalities including multiorgan hyperplasia and pituitary tumours (Nakayama et al, 1996) . Furthermore, the higher the levels of p27 KIP1 expression, the better the prognosis with regard to human malignant gliomas (Alleyne et al, 1999) , breast cancer (Porter et al, 1997) or lung cancer (Esposito et al, 1997) . Therefore, introduction of p27 KIP1 gene into tumour cells is expected to be a promising strategy to inhibit their malignant cellular proliferation.
It has been controversial whether p27 KIP1 expression leads tumour cells to growth arrest or cell death. Some groups demonstrate the induction of growth arrest by p27
KIPl (Sherr and Roberts, 1995; Craig et al, 1997) . Others show that p27 KIP1 expression induces apoptosis in several cell lines Schreiber et al, 1999) , while p27
KIPl protects cells from apoptosis (Hiromura et al, 1999) . In the present study, p27 KIP1 induced autophagic cell death, but not apoptosis in malignant glioma cells. Recently, several groups have proposed two types of programmed cell death (Schwartz et al, 1993; Bursch et al, 2000) . Type I programmed cell death, or apoptosis, is mediated by caspases/bcl family, and has typical morphological and biochemical characteristics such as chromatin condensation or nucleosomal ladder formation. Since TUNEL-positive cells were not detected in p27 KIP1 -infected U373-MG cells in the present study, it is unlikely that apoptosis is involved in the antitumour effect of p27 KIP1 on malignant glioma cells. In contrast, type II programmed cell death is marked morphologically by increased autophagy and early destruction of the cytoplasm that occur either without nuclear collapse or precedes it (Schwartz et al, 1993; Bursch et al, 2000) . More recently, Paglin et al (2001) demonstrated that formation of acidic vesicles was detected in radiation-induced autophagy. Since the development of AVO was detected in p27 KIP1 -infected U373-MG cells, we suggest that the antitumour effect of p27 KIP1 on malignant glioma cells is mainly because of induction of type II programmed cell death, autophagy. Further study is necessary to investigate the molecular mechanisms underlying p27 KIP1 -induced autophagy in malignant glioma cells. In summary, p27 KIP1 shows the most potent antitumour effect against malignant glioma cells, while cultured astrocytes are insensitive to p27
KIPl expression. The effect is because of autophagic cell death as well as G0/G1 growth arrest. Therefore, we expect that p27 KIP1 -based therapy for malignant gliomas might be a promising approach that is worth exploring further. 
